BACKGROUND: Multiple sclerosis (MS) is a heterogeneous neurologic disease with extensive variation with respect to the most affected central nervous system region (brain vs spinal cord). OBJECTIVE: To test the hypothesis that this variation in lesion location (brain vs spinal cord) might be (partially) genetically determined. DESIGN: Candidate gene study. SETTING: Academic research. PATIENTS: Patients were selected for the availability of DNA material, clinical variables, and brain and spinal cord magnetic resonance images (evaluating T2-weighted lesion load in the brain and the number of spinal cord lesions). MAIN OUTCOME MEASURES: For genotyping, we used a DNA chip containing a set of genes mentioned in previous publications noting their relation to different phenotypes of MS. We assessed the association between brain and spinal cord abnormalities and the genotypes of the patients. RESULTS: One hundred fifty patients were included in the analysis. Five single-nucleotide polymorphisms within the major histocompatibility complex region were associated with the number of focal abnormalities in the spinal cord. The most significant was rs3135388 (surrogate marker for the HLA-DRB1*1501 allele). Carriers of HLA-DRB1*1501 had a median of 4 spinal cord lesions compared with 2 lesions for noncarriers (P < .001). No significant association was noted between the single-nucleotide polymorphisms and T2-weighted lesion load in the brain. CONCLUSIONS: Carriership of HLA-DRB1*1501 (via rs3135388) was associated with the extent of focal abnormalities in the spinal cord. Spinal cord lesions might be an explanation for increased MS disease severity in patients carrying HLA-DRB1*1501.
BACKGROUND:Multiple sclerosis (MS) is a heterogeneous neurologic disease with extensive variation with respect to the most affected central nervous system region (brain vs spinal cord). OBJECTIVE: To test the hypothesis that this variation in lesion location (brain vs spinal cord) might be (partially) genetically determined. DESIGN: Candidate gene study. SETTING: Academic research. PATIENTS: Patients were selected for the availability of DNA material, clinical variables, and brain and spinal cord magnetic resonance images (evaluating T2-weighted lesion load in the brain and the number of spinal cord lesions). MAIN OUTCOME MEASURES: For genotyping, we used a DNA chip containing a set of genes mentioned in previous publications noting their relation to different phenotypes of MS. We assessed the association between brain and spinal cord abnormalities and the genotypes of the patients. RESULTS: One hundred fifty patients were included in the analysis. Five single-nucleotide polymorphisms within the major histocompatibility complex region were associated with the number of focal abnormalities in the spinal cord. The most significant was rs3135388 (surrogate marker for the HLA-DRB1*1501 allele). Carriers of HLA-DRB1*1501 had a median of 4 spinal cord lesions compared with 2 lesions for noncarriers (P < .001). No significant association was noted between the single-nucleotide polymorphisms and T2-weighted lesion load in the brain. CONCLUSIONS: Carriership of HLA-DRB1*1501 (via rs3135388) was associated with the extent of focal abnormalities in the spinal cord. Spinal cord lesions might be an explanation for increased MS disease severity in patients carrying HLA-DRB1*1501.
Authors: Adam B Cohen; Mohit Neema; Ashish Arora; Elisa Dell'oglio; Ralph H B Benedict; Shahamat Tauhid; Daniel Goldberg-Zimring; Christian Chavarro-Nieto; Antonella Ceccarelli; Joshua P Klein; James M Stankiewicz; Maria K Houtchens; Guy J Buckle; David C Alsop; Charles R G Guttmann; Rohit Bakshi Journal: J Neuroimaging Date: 2011-03-29 Impact factor: 2.486
Authors: Carmen Tur; Sreeram Ramagopalan; Daniel R Altmann; Benedetta Bodini; Mara Cercignani; Zhaleh Khaleeli; David H Miller; Alan J Thompson; Olga Ciccarelli Journal: Neurology Date: 2014-10-08 Impact factor: 9.910
Authors: Keren Regev; Brian C Healy; Fariha Khalid; Anu Paul; Renxin Chu; Shahamat Tauhid; Subhash Tummala; Camilo Diaz-Cruz; Radhika Raheja; Maria A Mazzola; Felipe von Glehn; Pia Kivisakk; Sheena L Dupuy; Gloria Kim; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi; Rohit Bakshi Journal: JAMA Neurol Date: 2017-03-01 Impact factor: 18.302
Authors: M H Sombekke; M M Vellinga; B M J Uitdehaag; F Barkhof; C H Polman; D Arteta; D Tejedor; A Martinez; J B A Crusius; A S Peña; J J G Geurts; H Vrenken Journal: AJNR Am J Neuroradiol Date: 2011-03-24 Impact factor: 3.825
Authors: B C Healy; M Liguori; D Tran; T Chitnis; B Glanz; C Wolfish; S Gauthier; G Buckle; M Houtchens; L Stazzone; S Khoury; R Hartzmann; M Fernandez-Vina; D A Hafler; H L Weiner; C R G Guttmann; P L De Jager Journal: Neurology Date: 2010-08-17 Impact factor: 9.910